Skip Navigation

COVID-19 Update

Clinical Trials

Your participation will allow you to have firsthand experience with developing new medical treatments that may be beneficial to other patients with shoulder injuries and degenerative conditions. Clinical trial information is excerpted from www.clinicaltrials.gov.

Open Trials

Conventus CAGE™ PH for use in Proximal Humerus Fracture Fixation Doc. Post-Approval Prospective Study

Location: Howard County General Hospital, Johns Hopkins Hospital
Investigators: Uma Srikumaran, M.D., Greg Osgood, M.D., Babar Shafiq, M.D., M.S.
Contact: Sabrina Jenkins; 443-546-1558; sjenki43@jhmi.edu

The PH Cage device was designed by Conventus Orthopaedics to fix broken shoulders. The PH Cage device is FDA approved and is a permanent implant that holds the broken bones together.

The purpose of this study is to determine:

  • Device safety and patient outcome data
  • Device usage data
  • Performance data for the implant procedure
  • Early economic benefit data

Eligibility Criteria:

  • Proximal humerus fracture
  • No open wound fractures
  • No allergies to nickel/titanium

Learn more about this study

A Post-Market Clinical Follow-up Study of the TITAN™ Reverse Shoulder System used in Primary or Revision Total Shoulder Arthroplasty

Location: Howard County General Hospital
Length: 10 years
InvestigatorsUma Srikumaran, M.D.
Contact: Sabrina Jenkins; 443-546-1558; sjenki43@jhmi.edu

The TITAN™ Reverse Shoulder System (TRS) device is cleared by FDA for the treatment of shoulder diseases requiring shoulder replacement. This research is being done to see how the device does over time and to collect more information about its safety and efficacy.

Eligibility Criteria:

  • Primary or revision total shoulder replacement for shoulder arthritis or fracture
  • Grossly deficient rotator cuff
  • Functional deltoid muscle

Learn more about this study

A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® TitanTM Modular Shoulder System 2.5 for Primary Shoulder Joint Replacement

Location: Howard County General Hospital
Length: 10 years
Investigators: Uma Srikumaran, M.D.
Contact: Sabrina Jenkins; 443-546-1558; sjenki43@jhmi.edu

The Titan 2.5 is a FDA approved joint replacement device designed to treat pain, limited motion, or weakness in the shoulder. This research is being done to see how the TITAN™ 2.5 device does over time and to collect more information about its safety and efficacy.

Eligibility Criteria:

  • Osteoarthritis, traumatic/rheumatoid arthritis, fractures or dislocations of shoulder
  • Repairable rotator cuff tears

Learn more about this study

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Location: Howard County General Hospital
Length: 27 weeks
Investigators: Uma Srikumaran, M.D.
Contact: Sabrina Jenkins; 443-546-1558; sjenki43@jhmi.edu

This is a research study to test an investigational study drug called FX006. FX006 has previously been FDA approved for the treatment of knee osteoarthritis pain. This research study now aims to see if an injection of FX006 into the shoulder joint can be used to treat patients with shoulder arthritis or frozen shoulder.

Participants in this study will be compensated up to $1100.00 for completion of study diaries and visits.

Study participants will be randomly assigned to receive either the placebo or FX006. They will not know whether they received FX006 or a placebo until the clinical research study is completed.

Eligibility Criteria:

  • Age: 35-80 years
  • Shoulder arthritis OR frozen shoulder
  • Can only take Tylenol during study for pain control

Learn more about this study

back to top button